Royal Bank of Canada Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM)

Research analysts at Royal Bank of Canada assumed coverage on shares of Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set an "outperform" rating and a $30.00 price target on the stock. Royal Bank of Canada's price target would indicate a potential upside of 92.31% from the company's previous close.

Several other equities research analysts have also weighed in on the company. Morgan Stanley assumed coverage on Contineum Therapeutics in a research note on Tuesday. They set an "overweight" rating and a $25.00 price objective for the company. Stifel Nicolaus assumed coverage on Contineum Therapeutics in a report on Tuesday. They set a "buy" rating and a $29.00 price target on the stock.

Contineum Therapeutics Price Performance

Shares of CTNM traded down $0.40 during trading hours on Tuesday, hitting $15.60. 88,111 shares of the company were exchanged, compared to its average volume of 88,454. Contineum Therapeutics has a one year low of $13.90 and a one year high of $16.06.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).